How to Start a Pharmacist-Led Anticoagulation Clinic from Scratch
Anticoagulants continue to be among the most prescribed therapeutic classes across Australia, with millions of repeats dispensed each year through community pharmacies. Warfarin retains a strong foothold in cardiology for mechanical valves and recurrent thrombosis, while direct oral anticoagulants dominate new starts for atrial fibrillation and venous thromboembolism. Each drug class carries its own complexity: warfarin demands tight international normalised ratio control, and DOACs require persistent vigilance around renal function, drug interactions and adherence.
Building a pharmacist-led anticoagulation clinic from a single desk and a booking diary is achievable when the foundations are sound. This article walks through the clinical rationale, governance pathways, workflow design and funding models that turn an idea into a functioning service. Context examples reference Australian realities in cities like Brisbane, Sydney, Adelaide and Perth, alongside regional areas where telehealth often closes the gap between patient and pharmacist.
Establishing the clinical rationale in Australian pharmacy
Pharmacist-led anticoagulation clinics have a strong evidence base internationally, and the Australian setting adds its own pressure points. Roughly one in four adults in Australia lives with atrial fibrillation, and stroke hospitalisations have risen over the past decade despite improvements in primary prevention. Anticoagulant-related bleeding admissions cost the health system hundreds of millions each year, and most events are linked to modifiable factors: poor adherence, drifting INR, drug interactions and inadequate monitoring at transitions of care.
Structured monitoring, timely intervention and patient education reduce bleeding and thromboembolic events, and pharmacists are well placed to deliver all three. In regional Queensland and Western Australia, where access to specialist clinics is limited, pharmacist-led warfarin management has already demonstrated improvements in time in therapeutic range. The case for a clinic responds to a measurable gap that general practice and tertiary services are struggling to close alone.
Credentialing, governance and professional scope
Before seeing a single patient, the pharmacist needs the right credentials and a clear governance framework. AHPRA registration is the floor, not the ceiling. Credentialing through the Pharmaceutical Society of Australia, including the CP-Cred pathway, signals competence in medication management reviews and collaborative prescribing support. Many warfarin clinic pharmacists also pursue post-graduate qualifications in clinical pharmacy practice.
Once credentialed, the clinic needs a defined scope of practice, clinical protocols and a supervising medical practitioner or governance committee. Key elements include:
- Written collaborative agreements with the supervising GP or specialist, outlining referral pathways, escalation triggers and shared decision rules.
- Documented clinical protocols covering warfarin initiation, dose adjustment under medical delegation, DOAC review and bleeding risk assessment using tools such as HAS-BLED.
- A clear incident and complaint pathway, with regular audit of outcomes and near misses.
- Documentation that integrates with the patient's usual GP and any specialist, in line with Australian Digital Health Agency conventions.
In Sydney and Melbourne, this often means working alongside an established cardiology or haematology unit; in Hobart or Darwin, the relationship might be with a regional tertiary service. The clinic design must accommodate both.
Designing the patient pathway and clinical workflow
A reliable workflow is the backbone of any anticoagulation service. From the moment a referral arrives, the pathway should be predictable for the patient, the referring GP and the supervising clinician.
Start with a structured intake. Capture indication, target INR range if warfarin is in play, baseline renal and hepatic function, full medication and complementary medicines list, bleeding and thrombosis history, and lifestyle factors relevant to adherence. Many clinics in Australia now run a hybrid intake: paper forms collected at the community pharmacy, followed by a 20 to 40 minute face-to-face or telehealth appointment at a dedicated time.
The clinical encounter then follows a layered structure. For warfarin, point-of-care INR testing produces a result within minutes; dose adjustments are made under protocol, and the patient leaves with a printed plan, the next appointment date and a clear contact for bleeding concerns. For DOACs, the encounter is more conversational, focusing on adherence, renal function trending, gastroprotection and interaction review. Documentation flows back to the GP and supervising clinician on the same day. The cleanest implementations often borrow ideas from practitioners like Johnathan Laird, whose work on pharmacist-led anticoagulation has shaped UK practice and translates well to Australian models.
Building referral networks with GPs and specialists
A clinic without referrals is an empty waiting room. Building the network needs deliberate effort, and the strongest anticoagulation services in Australia usually start with a small circle of engaged GPs and then expand outward.
Engage the local Primary Health Network early. PHNs in places like Western Sydney, North Western Melbourne and the Hunter Region actively seek pharmacist-led services to support chronic disease management, and some will co-fund pilots or assist with population health data. Host a short GP education evening on the service, share a simple referral form, and commit to feedback turnaround that GP practices actually trust.
Hospitals are another rich source. Haematology, cardiology and orthopaedic wards routinely discharge patients on anticoagulants who need structured follow-up. A formal pathway with the hospital pharmacy department creates a steady intake and reduces readmissions, with the clinic feeding back to the hospital team if anything unusual emerges.
Side by side, the practical dimensions most often raised by GP referrers look like this:
| Dimension | Warfarin-led clinic | DOAC optimisation clinic |
|---|---|---|
| Initial patient contact | Point-of-care INR testing and structured review | Adherence and renal function assessment |
| Visit frequency | Every 1 to 4 weeks depending on stability | Every 3 to 6 months |
| Time per encounter | 15 to 25 minutes | 20 to 30 minutes |
| Key tools | CoaguChek XS Plus, dosing protocols, decision support | Renal function trending, interaction checker |
| Escalation triggers | INR outside range, bleeding, missed doses | Adherence drop, CrCl below 50 mL/min, dual antiplatelet therapy |
| Funding pathways | MedsCheck, HMR, private billing under arrangement | MedsCheck, private consultation fee, condition-specific arrangements |
Tools, INR systems and outcome tracking
The right tools elevate an anticoagulation clinic from a paperwork exercise to a measurable service. Point-of-care INR devices such as the CoaguChek XS Plus and Roche Prothrombin Time systems are used widely in Australian community clinics, with quality control procedures set by the National Pathology Accreditation Advisory Council.
Outcome tracking matters as much as the device. Set up a simple database that records indication, INR or DOAC, last result, adverse events, hospital admissions and target range achievement. Even a well-structured Excel workbook, when audited quarterly, gives the supervising governance committee and the funder something to review. Safety reflections shared on Thamburaj's clinical perspectives consistently emphasise that outcome transparency is the foundation on which funding credibility is built.
Useful operational pillars to support a new clinic include:
- A defined annual audit cycle aligned with the financial year, so reporting lines up with Medicare and PHN cycles.
- A patient registry that flags high-risk patients automatically when renal function deteriorates or a high-risk drug is dispensed.
- Regular continuing professional development for the team, including journal clubs focused on emerging DOAC evidence and reversal strategies.
- Quality improvement reviews every quarter, with results shared back to GPs to reinforce trust in the referral pathway.
Funding models, sustainability and scaling the service
Sustainability is where many well-intentioned services falter. Australian pharmacists do not currently have direct access to Medicare item numbers for standalone anticoag consultations, so the model usually blends several revenue streams. Community pharmacists can deliver MedsCheck and Diabetes MedsCheck reviews, with anticoagulation review embedded as part of a chronic disease consultation. Home Medicines Reviews remain an option for housebound patients, while Residential Medication Management Reviews work in aged care facilities where warfarin and DOACs are common. Private consultation fees are increasingly accepted in metropolitan areas including Perth and the greater Brisbane region, particularly when bundled with a structured annual review.
Scaling comes through three levers. Expand the referral catchment by engaging more GPs and adding specialists such as neurology for non-valvular atrial fibrillation and nephrology for patients with deteriorating renal function. Embed the service into pharmacy training by supervising intern placements and post-graduate students, which builds workforce capacity while reducing supervision costs. Document outcomes in a publishable format: an annual report summarising time in therapeutic range, bleeding events, adherence markers and patient-reported experience gives the clinic a competitive edge when negotiating with funders and PHNs.
The final step is registration with QCPP or an equivalent quality programme to formalise standards and provide a credentialing footprint for future expansion into prescribing arrangements as Australian scope of practice evolves. Each of these moves shifts the clinic beyond a one-pharmacist experiment and into an embedded service.
Setting up a pharmacist-led anticoagulation clinic is not a project to finish but a service to grow. Start with one credentialed pharmacist, one supervising GP, a single room with a point-of-care INR device, and a clearly written protocol. Treat the first six months as a pilot with measured outcomes, then refine the workflow and broaden the network. Reach out to local Primary Health Networks, hospital pharmacy departments and rural workforce agencies to align with regional priorities, and explore the credentialing pathways offered by PSA and SHPA for ongoing professional development. Commit to documenting every outcome so that the next pharmacist stepping into anticoagulation work inherits something stronger than a good idea.